Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMICE: Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer
2016-004215-13Phase 2Unknown
- Sponsor
- Clatterbridge Cancer Centre
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cervical Cancer (CC) comparing Cediranib + Olaparib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
cediranibolaparib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2016-004215-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004215-13.